

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

NCI-N87

RRID:CVCL_1603

Type: Cell Line

Proper Citation

RRID:CVCL_1603

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1603

Proper Citation: RRID:CVCL_1603

Description: Cell line NCI-N87 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Gastric tubular adenocarcinoma

Defining Citation: [PMID:1676761](#), [PMID:2158397](#), [PMID:8806089](#), [PMID:8806092](#), [PMID:8806095](#), [PMID:18804159](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24807215](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:26919099](#), [PMID:27102572](#), [PMID:27397505](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Caution: According to PubMed=1676761 the ethnicity of the donor is Caucasian, but exome analysis finds it to be mostly of African lineage., Characteristics: Established from a nude mouse xenograft., Part of: MET genetic alteration cell panel (ATCC TCP-1036)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-N87

Synonyms: NCI N87, N87, N-87, NCI-H87, H87, H-87, NCIN87

Cross References: BTO:BTO_0003053, CLO:CLO_0008129, EFO:EFO_0002841, AddexBio:C0023002/4674, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706,

ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5822, BCRC:60217, BCRJ:0350, BioGRID_ORCS_Cell_line:516, BioSample:SAMN01120666, BioSample:SAMN03473211, BioSample:SAMN10987913, cancercellines:CVCL_1603, CCRID:1101HUM-PUMC000481, CCRID:3101HUMSCSP534, CCRID:3101HUMTCHu130, CCRID:4201HUM-CCTCC00256, CCTCC:GDC0256, Cell_Model_Passport:SIDM01147, ChEMBL-Cells:ChEMBL3307326, ChEMBL-Targets:ChEMBL614197, CLS:305057, Cosmic:685598, Cosmic:687556, Cosmic:868236, Cosmic:887250, Cosmic:908461, Cosmic:1187286, Cosmic:1482074, Cosmic:1582431, Cosmic:1995594, Cosmic:2036661, Cosmic:2069775, Cosmic:2443800, Cosmic:2484955, Cosmic:2807636, Cosmic:2823228, Cosmic-CLP:908461, DepMap:ACH-000427, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908461, GEO:GSM267420, GEO:GSM267427, GEO:GSM267434, GEO:GSM267441, GEO:GSM552366, GEO:GSM562405, GEO:GSM827404, GEO:GSM828827, GEO:GSM844665, GEO:GSM887453, GEO:GSM888533, GEO:GSM1237678, GEO:GSM1237703, GEO:GSM1374768, GEO:GSM1374769, GEO:GSM1374770, GEO:GSM1670272, IARC_TP53:305, IZSLER:BS TCL 224, KCB:KCB 2010183YJ, KCLB:60113, KCLB:60187, LiGeA:CCL_561, LINCS_LDP:LCL-1886, PharmacDB:NCIN87_1151_2019, PRIDE:PXD030304, Progenetix:CVCL_1603, PubChem_Cell_line:CVCL_1603, Ubigen:YC-C068, Wikidata:Q54908217

ID: CVCL_1603

Record Creation Time: 20220427T220841+0000

Record Last Update: 20260905T181248+0000

Ratings and Alerts

No rating or validation information has been found for NCI-N87.

Warning: Discontinued: KCLB; 60187

Caution: According to PubMed=1676761 the ethnicity of the donor is Caucasian, but exome analysis finds it to be mostly of African lineage., Characteristics: Established from a nude mouse xenograft., Part of: MET genetic alteration cell panel (ATCC TCP-1036)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 685 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Shen X, et al. (2026) A novel circSLIT2-encoded SLIT2 isoform suppresses neural invasion in gastric cancer. *Oncogene*, 45(31), 3181.

Kopp A, et al. (2026) In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. *Molecular cancer therapeutics*, 25(4), 610.

Li L, et al. (2026) The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer. *Frontiers in oncology*, 16, 1728472.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. *Nature communications*, 17(1), 759.

Zhang J, et al. (2026) Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer. *International immunopharmacology*, 175, 116453.

Laurenziello P, et al. (2026) Salinomycin as a death switch: how gastric cancer cells choose their demise. *Cell death discovery*, 12(1).

Huang F, et al. (2026) Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer. *iScience*, 29(6), 115849.

Xie YL, et al. (2026) Ubiquitin Specific Peptidase 48 Deubiquitinates METTL3 to Modulate Ferroptosis in Gastric Cancer Cells. *Molecular carcinogenesis*.

Lu Y, et al. (2026) GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. *Cancer research*, 86(10), 2429.

He J, et al. (2026) UBE2B Drives NF- κ B Signaling and Gastric Cancer Progression through BIRC2-Mediated K63-Linked Ubiquitination of TRAF1. *Molecular cancer research : MCR*, 24(6), 487.

Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. *Pharmaceuticals (Basel, Switzerland)*, 19(4).

Wang X, et al. (2026) Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. *Cell reports. Medicine*, 7(7), 102885.

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Wei D, et al. (2026) OSMR coordinates a self-perpetuating circuit linking chemoresistance and neutrophil-driven immunosuppression in gastric cancer. *Neoplasia (New York, N.Y.)*, 73, 101279.

Shanmugam MK, et al. (2026) Bioorthogonal catalytic centres engineered for gastrointestinal stabilization provide oral delivery for the treatment of gastric cancer. *Journal of nanobiotechnology*, 24(1).

Zhao C, et al. (2026) Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A. *Cell death & disease*, 17(1).

L??chen AA, et al. (2026) Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy. *Molecular oncology*.

Yu BM, et al. (2026) Yes-Associated Protein Drives Helicobacter pylori-Induced Metaplastic Changes in Gastric Epithelium. *Cellular and molecular gastroenterology and hepatology*, 20(9), 101814.